ESI-GROUP/FAW-VW
2.4.2024 08:01:33 CEST | Business Wire | Press release
Regulatory News:
ESI Group (Paris:ESI) and FAW-Volkswagen (FAW-VW) TE have commemorated their strategic partnership with the signing of a Memorandum of Understanding (MoU) aimed at advancing intelligent simulation technology within the automotive industry. The ceremony, held at the FAW-VW R&D center in Changchun, Jilin Province, PRC, was officiated by Deng Guohui, Technical Development Director at FAW-VW, and Francis Griffiths, Executive Vice-President and Chief Revenue Officer at ESI Group.
The collaboration between ESI Group and FAW-VW TE aims to address the challenges posed by China's automotive safety regulations and drive industry innovation. Through this partnership, the two entities will aim to drive innovation and efficiency in intelligent simulation, and work towards establishing a localized automotive industry material database, thereby enhancing cooperation in advancing intelligent simulation technology across the industry. This collaborative effort is geared toward paving the way for a cleaner, safer, and more productive future.
Under the MoU, a material testing and intelligent simulation joint laboratory has been established, marking a significant step forward in intelligent simulation, innovation, and research within the automotive sector.
“With over 40 years of collaboration, ESI Group and VW Group have built strong ties, including a fruitful partnership with FAW-VW since 2007. This marks a significant milestone in our commitment to advancing virtual simulation technology in the automotive sector. Together with FAW-Volkswagen, we aim to drive innovation and efficiency in intelligent simulation, materials research and development,” declared Francis Griffiths, Executive Vice-President, Chief Revenue Officer at ESI Group.
"Today's milestone event celebrates not only two decades of fruitful collaboration but also embarks on a new era of innovation in automotive virtual simulation with ESI. This partnership signifies more than a formal agreement; it is a testament to our shared vision and commitment, aiming to pioneer intelligent simulation and materials research, setting new industry standards, and driving automotive safety and efficiency forward." declared Deng Guohui, Technical Development Director at FAW-VW.
During the ceremony, FAW-VW TE and ESI Group exchanged awards to honor their collaborative achievements in innovation. FAW-VW TE awarded ESI Group the prestigious "CAE Trusted Advisor" award, recognizing ESI's outstanding support in advancing virtual simulation technology in the automotive industry.
ESI Group reciprocated by presenting multiple global awards to FAW-VW's Technology Development team, including "Best Cooperation Partner" represented by Deng Guohui, Technical Development Director at FAW-VW and "Best Simulation Method Development Team" represented by Fu Xiaolong. Li Dapeng was also honored with the "'Virtual Performance Expert" award for their exceptional contributions. These accolades underscore the mutual respect, shared goals, and commitment of both companies to advancing automotive safety and efficiency through successful collaboration.
About ESI Group
ESI Group, a part of Keysight Technologies, provides reliable and customized solutions anchored on predictive physics modeling and virtual prototyping expertise. Acting principally in automotive, land transportation, aerospace and defense, and heavy industry, ESI software enables engineers to simulate mechanical designs, smart manufacturing processes, and human-centric workflows to make better decisions earlier in the product lifecycle. Keysight is an S&P 500 company delivering market-leading design, emulation, and test solutions to help engineers develop and deploy faster, with less risk, throughout the entire product lifecycle. For further information, go to: www.esi-group.com
Follow ESI LinkedIn | Facebook | Twitter | YouTube
About FAW-Volkswagen
Established on February 6, 1991, FAW-Volkswagen Automotive Co., Ltd. (hereinafter referred to as FAW-Volkswagen) is a large-sized passenger auto manufacturer jointly managed by First Automotive Group Corporation, Volkswagen AG, Audi AG and Volkswagen (China) Investment Co., Ltd. It is the domestic first modern passenger auto manufacturer constructed according to the economic scale.
Through the development of around 30 years, FAW-Volkswagen has had the capacity layout in Changchun in the Northeast, Chengdu in the Southwest, Foshan in South China, Qingdao in East China and Tianjin in North China. It boasts eight professional manufacturing factories, namely No. 1 Car Factory, No. 2 Car Factory, No. 3 Car Factory, No. 4 Car Factory, No. 5 Car Factory, No. 6 Car Factory, Business Division of Power Assembly, and Punching Center.
Add: No. 5 Anqing Road, Auto Industry Development District, Changchun Jilin Province, PRC
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240401600103/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 15:00:00 CEST | Press release
Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release
Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom